ID   MK13_HUMAN              Reviewed;         365 AA.
AC   O15264; O14739; O15124; Q5U4A5; Q6FI46; Q9UNU0;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   12-OCT-2022, entry version 208.
DE   RecName: Full=Mitogen-activated protein kinase 13;
DE            Short=MAP kinase 13;
DE            Short=MAPK 13;
DE            EC=2.7.11.24;
DE   AltName: Full=Mitogen-activated protein kinase p38 delta;
DE            Short=MAP kinase p38 delta;
DE   AltName: Full=Stress-activated protein kinase 4;
GN   Name=MAPK13; Synonyms=PRKM13, SAPK4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ACTIVITY REGULATION.
RC   TISSUE=Pituitary;
RX   PubMed=9218798; DOI=10.1093/emboj/16.12.3563;
RA   Goedert M., Cuenda A., Craxton M., Jakes R., Cohen P.;
RT   "Activation of the novel stress-activated protein kinase SAPK4 by cytokines
RT   and cellular stresses is mediated by SKK3 (MKK6); comparison of its
RT   substrate specificity with that of other SAP kinases.";
RL   EMBO J. 16:3563-3571(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PHOSPHORYLATION AT THR-180 AND
RP   TYR-182, MUTAGENESIS OF THR-180 AND TYR-182, ACTIVITY REGULATION, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=9374491; DOI=10.1074/jbc.272.48.30122;
RA   Jiang Y., Gram H., Zhao M., New L., Gu J., Feng L., Di Padova F.,
RA   Ulevitch R.J., Han J.;
RT   "Characterization of the structure and function of the fourth member of p38
RT   group mitogen-activated protein kinases, p38delta.";
RL   J. Biol. Chem. 272:30122-30128(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9295308; DOI=10.1074/jbc.272.38.23668;
RA   Wang X.S., Diener K., Manthey C.L., Wang S.-W., Rosenzweig B., Bray J.,
RA   Delaney J., Cole C., Zukowski M., Yao Z.;
RT   "Molecular cloning and characterization of a novel p38 mitogen-activated
RT   protein kinase.";
RL   J. Biol. Chem. 272:23668-23674(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9207191; DOI=10.1006/bbrc.1997.6849;
RA   Kumar S., McDonnell P.C., Gum R.J., Hand A.T., Lee J.C., Young P.R.;
RT   "Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity
RT   and sensitivity to inhibition by pyridinyl imidazoles.";
RL   Biochem. Biophys. Res. Commun. 235:533-538(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=10066767; DOI=10.1074/jbc.274.11.7095;
RA   Hu M.C.-T., Wang Y.-P., Mikhail A., Qiu W.R., Tan T.-H.;
RT   "Murine p38-delta mitogen-activated protein kinase, a developmentally
RT   regulated protein kinase that is activated by stress and proinflammatory
RT   cytokines.";
RL   J. Biol. Chem. 274:7095-7102(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=10727080; DOI=10.3109/10425179909033952;
RA   Herbison C.E., Sayer D.C., Bellgard M., Allcock R.J.N., Christiansen F.T.,
RA   Price P.;
RT   "Structure and polymorphism of two stress-activated protein kinase genes
RT   centromeric of the MHC: SAPK2a and SAPK4.";
RL   DNA Seq. 10:229-243(1999).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Lung, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF STMN1.
RX   PubMed=9731215; DOI=10.1006/bbrc.1998.9250;
RA   Parker C.G., Hunt J., Diener K., McGinley M., Soriano B., Keesler G.A.,
RA   Bray J., Yao Z., Wang X.S., Kohno T., Lichenstein H.S.;
RT   "Identification of stathmin as a novel substrate for p38 delta.";
RL   Biochem. Biophys. Res. Commun. 249:791-796(1998).
RN   [13]
RP   TISSUE SPECIFICITY.
RX   PubMed=10201954;
RA   Hale K.K., Trollinger D., Rihanek M., Manthey C.L.;
RT   "Differential expression and activation of p38 mitogen-activated protein
RT   kinase alpha, beta, gamma, and delta in inflammatory cell lineages.";
RL   J. Immunol. 162:4246-4252(1999).
RN   [14]
RP   INTERACTION WITH MAPK8IP2.
RX   PubMed=11378392; DOI=10.1016/s0960-9822(01)00232-9;
RA   Schoorlemmer J., Goldfarb M.;
RT   "Fibroblast growth factor homologous factors are intracellular signaling
RT   proteins.";
RL   Curr. Biol. 11:793-797(2001).
RN   [15]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=11500363; DOI=10.1093/emboj/20.16.4360;
RA   Knebel A., Morrice N., Cohen P.;
RT   "A novel method to identify protein kinase substrates: eEF2 kinase is
RT   phosphorylated and inhibited by SAPK4/p38delta.";
RL   EMBO J. 20:4360-4369(2001).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF MAPT.
RX   PubMed=11943212; DOI=10.1016/s0014-5793(02)02460-2;
RA   Buee-Scherrer V., Goedert M.;
RT   "Phosphorylation of microtubule-associated protein tau by stress-activated
RT   protein kinases in intact cells.";
RL   FEBS Lett. 515:151-154(2002).
RN   [17]
RP   FUNCTION IN PHOSPHORYLATION OF MAPT.
RX   PubMed=15632108; DOI=10.1242/jcs.01655;
RA   Feijoo C., Campbell D.G., Jakes R., Goedert M., Cuenda A.;
RT   "Evidence that phosphorylation of the microtubule-associated protein Tau by
RT   SAPK4/p38delta at Thr50 promotes microtubule assembly.";
RL   J. Cell Sci. 118:397-408(2005).
RN   [18]
RP   FUNCTION IN KERATINOCYTE APOPTOSIS.
RX   PubMed=17256148; DOI=10.1007/s00403-006-0727-4;
RA   Kraft C.A., Efimova T., Eckert R.L.;
RT   "Activation of PKCdelta and p38delta MAPK during okadaic acid dependent
RT   keratinocyte apoptosis.";
RL   Arch. Dermatol. Res. 299:71-83(2007).
RN   [19]
RP   FUNCTION IN PHOSPHORYLATION OF MYB.
RX   PubMed=18006338; DOI=10.1016/j.bcmd.2007.09.010;
RA   Pani E., Ferrari S.;
RT   "p38MAPK delta controls c-Myb degradation in response to stress.";
RL   Blood Cells Mol. Dis. 40:388-394(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-47, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [21]
RP   DEPHOSPHORYLATION BY DUSP1, AND FUNCTION.
RX   PubMed=18367666; DOI=10.1073/pnas.0801453105;
RA   Zhou X., Ferraris J.D., Dmitrieva N.I., Liu Y., Burg M.B.;
RT   "MKP-1 inhibits high NaCl-induced activation of p38 but does not inhibit
RT   the activation of TonEBP/OREBP: opposite roles of p38alpha and p38delta.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:5620-5625(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-350, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [23]
RP   FUNCTION.
RX   PubMed=20478268; DOI=10.1016/j.bbrc.2010.05.072;
RA   Ozawa S., Ito S., Kato Y., Kubota E., Hata R.;
RT   "Human p38 delta MAP kinase mediates UV irradiation induced up-regulation
RT   of the gene expression of chemokine BRAK/CXCL14.";
RL   Biochem. Biophys. Res. Commun. 396:1060-1064(2010).
RN   [24]
RP   REVIEW ON FUNCTION.
RX   PubMed=20090411; DOI=10.4161/cc.9.3.10541;
RA   Efimova T.;
RT   "p38delta mitogen-activated protein kinase regulates skin homeostasis and
RT   tumorigenesis.";
RL   Cell Cycle 9:498-505(2010).
RN   [25]
RP   REVIEW ON ACTIVITY REGULATION, AND REVIEW ON FUNCTION.
RX   PubMed=20626350; DOI=10.1042/bj20100323;
RA   Cuadrado A., Nebreda A.R.;
RT   "Mechanisms and functions of p38 MAPK signalling.";
RL   Biochem. J. 429:403-417(2010).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.09 ANGSTROMS) OF 2-352.
RG   New York structural genomix research consortium (NYSGXRC);
RT   "Crystal structure of p38delta kinase.";
RL   Submitted (JUN-2009) to the PDB data bank.
RN   [28]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-41; VAL-282 AND THR-300.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine kinase which acts as an essential component
CC       of the MAP kinase signal transduction pathway. MAPK13 is one of the
CC       four p38 MAPKs which play an important role in the cascades of cellular
CC       responses evoked by extracellular stimuli such as pro-inflammatory
CC       cytokines or physical stress leading to direct activation of
CC       transcription factors such as ELK1 and ATF2. Accordingly, p38 MAPKs
CC       phosphorylate a broad range of proteins and it has been estimated that
CC       they may have approximately 200 to 300 substrates each. MAPK13 is one
CC       of the less studied p38 MAPK isoforms. Some of the targets are
CC       downstream kinases such as MAPKAPK2, which are activated through
CC       phosphorylation and further phosphorylate additional targets. Plays a
CC       role in the regulation of protein translation by phosphorylating and
CC       inactivating EEF2K. Involved in cytoskeletal remodeling through
CC       phosphorylation of MAPT and STMN1. Mediates UV irradiation induced up-
CC       regulation of the gene expression of CXCL14. Plays an important role in
CC       the regulation of epidermal keratinocyte differentiation, apoptosis and
CC       skin tumor development. Phosphorylates the transcriptional activator
CC       MYB in response to stress which leads to rapid MYB degradation via a
CC       proteasome-dependent pathway. MAPK13 also phosphorylates and down-
CC       regulates PRKD1 during regulation of insulin secretion in pancreatic
CC       beta cells. {ECO:0000269|PubMed:11500363, ECO:0000269|PubMed:11943212,
CC       ECO:0000269|PubMed:15632108, ECO:0000269|PubMed:17256148,
CC       ECO:0000269|PubMed:18006338, ECO:0000269|PubMed:18367666,
CC       ECO:0000269|PubMed:20478268, ECO:0000269|PubMed:9731215}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.24;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.24;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ACTIVITY REGULATION: Activated by phosphorylation on threonine and
CC       tyrosine by dual specificity kinases, MAP2K3/MKK3, MAP2K6/MKK6,
CC       MAP2K4/MKK4 and MAP2K7/MKK7. Activation by ultraviolet radiation,
CC       hyperosmotic shock, anisomycin or by TNF-alpha is mediated by
CC       MAP2K3/MKK3. Inhibited by dual specificity phosphatase DUSP1.
CC       {ECO:0000269|PubMed:11500363, ECO:0000269|PubMed:9218798,
CC       ECO:0000269|PubMed:9374491}.
CC   -!- SUBUNIT: Interacts with MAPK8IP2. {ECO:0000269|PubMed:11378392}.
CC   -!- INTERACTION:
CC       O15264; P21462: FPR1; NbExp=3; IntAct=EBI-2116951, EBI-2869495;
CC       O15264; Q15139: PRKD1; NbExp=6; IntAct=EBI-2116951, EBI-1181072;
CC       O15264; P40763: STAT3; NbExp=2; IntAct=EBI-2116951, EBI-518675;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O15264-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15264-2; Sequence=VSP_056558, VSP_056559;
CC   -!- TISSUE SPECIFICITY: Expressed in testes, pancreas, small intestine,
CC       lung and kidney. Abundant in macrophages, also present in neutrophils,
CC       CD4+ T-cells, and endothelial cells. {ECO:0000269|PubMed:10201954,
CC       ECO:0000269|PubMed:9374491}.
CC   -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues
CC       whose phosphorylation activates the MAP kinases.
CC   -!- PTM: Dually phosphorylated on Thr-180 and Tyr-182 by MAP2K3/MKK3,
CC       MAP2K4/MKK4, MAP2K6/MKK6 and MAP2K7/MKK7, which activates the enzyme.
CC       Dephosphorylated by dual specificity phosphatase DUSP1.
CC       {ECO:0000269|PubMed:9374491}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. MAP kinase subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MAPK13ID41291ch6p21.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y10488; CAA71512.1; -; mRNA.
DR   EMBL; U93232; AAB87639.1; -; mRNA.
DR   EMBL; AF015256; AAC51758.1; -; mRNA.
DR   EMBL; AF004709; AAC51374.1; -; mRNA.
DR   EMBL; AF092535; AAD23377.1; -; mRNA.
DR   EMBL; AF100546; AAF36772.1; -; mRNA.
DR   EMBL; BT007221; AAP35885.1; -; mRNA.
DR   EMBL; CR536490; CAG38729.1; -; mRNA.
DR   EMBL; Z95152; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471081; EAX03874.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX03875.1; -; Genomic_DNA.
DR   EMBL; BC000433; AAH00433.1; -; mRNA.
DR   EMBL; BC001641; AAH01641.1; -; mRNA.
DR   EMBL; BC004428; AAH04428.1; -; mRNA.
DR   EMBL; BC085196; AAH85196.1; -; mRNA.
DR   CCDS; CCDS4818.1; -. [O15264-1]
DR   PIR; JC5528; JC5528.
DR   RefSeq; NP_002745.1; NM_002754.4. [O15264-1]
DR   PDB; 3COI; X-ray; 2.09 A; A=2-352.
DR   PDB; 4EYJ; X-ray; 2.10 A; A=1-352.
DR   PDB; 4EYM; X-ray; 2.35 A; A=1-352.
DR   PDB; 4MYG; X-ray; 2.59 A; A/B=1-352.
DR   PDB; 4YNO; X-ray; 1.70 A; A=1-352.
DR   PDB; 5EKN; X-ray; 2.59 A; A=1-352.
DR   PDB; 5EKO; X-ray; 2.00 A; A=1-352.
DR   PDBsum; 3COI; -.
DR   PDBsum; 4EYJ; -.
DR   PDBsum; 4EYM; -.
DR   PDBsum; 4MYG; -.
DR   PDBsum; 4YNO; -.
DR   PDBsum; 5EKN; -.
DR   PDBsum; 5EKO; -.
DR   AlphaFoldDB; O15264; -.
DR   SMR; O15264; -.
DR   BioGRID; 111589; 45.
DR   IntAct; O15264; 112.
DR   MINT; O15264; -.
DR   STRING; 9606.ENSP00000211287; -.
DR   BindingDB; O15264; -.
DR   ChEMBL; CHEMBL2939; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB05157; KC706.
DR   DrugBank; DB01017; Minocycline.
DR   DrugCentral; O15264; -.
DR   GuidetoPHARMACOLOGY; 1502; -.
DR   iPTMnet; O15264; -.
DR   PhosphoSitePlus; O15264; -.
DR   BioMuta; MAPK13; -.
DR   CPTAC; CPTAC-876; -.
DR   CPTAC; CPTAC-877; -.
DR   EPD; O15264; -.
DR   jPOST; O15264; -.
DR   MassIVE; O15264; -.
DR   MaxQB; O15264; -.
DR   PaxDb; O15264; -.
DR   PeptideAtlas; O15264; -.
DR   PRIDE; O15264; -.
DR   ProteomicsDB; 48552; -. [O15264-1]
DR   ProteomicsDB; 65225; -.
DR   ABCD; O15264; 8 sequenced antibodies.
DR   Antibodypedia; 2088; 909 antibodies from 38 providers.
DR   DNASU; 5603; -.
DR   Ensembl; ENST00000211287.9; ENSP00000211287.4; ENSG00000156711.17. [O15264-1]
DR   Ensembl; ENST00000373766.9; ENSP00000362871.5; ENSG00000156711.17. [O15264-2]
DR   GeneID; 5603; -.
DR   KEGG; hsa:5603; -.
DR   MANE-Select; ENST00000211287.9; ENSP00000211287.4; NM_002754.5; NP_002745.1.
DR   UCSC; uc003ols.5; human. [O15264-1]
DR   CTD; 5603; -.
DR   DisGeNET; 5603; -.
DR   GeneCards; MAPK13; -.
DR   HGNC; HGNC:6875; MAPK13.
DR   HPA; ENSG00000156711; Tissue enhanced (esophagus).
DR   MIM; 602899; gene.
DR   neXtProt; NX_O15264; -.
DR   OpenTargets; ENSG00000156711; -.
DR   PharmGKB; PA30620; -.
DR   VEuPathDB; HostDB:ENSG00000156711; -.
DR   eggNOG; KOG0660; Eukaryota.
DR   GeneTree; ENSGT00940000159584; -.
DR   HOGENOM; CLU_000288_181_1_1; -.
DR   InParanoid; O15264; -.
DR   OMA; PFEHTLF; -.
DR   PhylomeDB; O15264; -.
DR   TreeFam; TF105100; -.
DR   BRENDA; 2.7.11.24; 2681.
DR   PathwayCommons; O15264; -.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-171007; p38MAPK events.
DR   Reactome; R-HSA-376172; DSCAM interactions.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   SignaLink; O15264; -.
DR   SIGNOR; O15264; -.
DR   BioGRID-ORCS; 5603; 17 hits in 1107 CRISPR screens.
DR   ChiTaRS; MAPK13; human.
DR   EvolutionaryTrace; O15264; -.
DR   GeneWiki; MAPK13; -.
DR   GenomeRNAi; 5603; -.
DR   Pharos; O15264; Tchem.
DR   PRO; PR:O15264; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; O15264; protein.
DR   Bgee; ENSG00000156711; Expressed in tongue squamous epithelium and 169 other tissues.
DR   ExpressionAtlas; O15264; baseline and differential.
DR   Genevisible; O15264; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004707; F:MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0072740; P:cellular response to anisomycin; IDA:UniProtKB.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IDA:UniProtKB.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IDA:UniProtKB.
DR   GO; GO:1903936; P:cellular response to sodium arsenite; IDA:UniProtKB.
DR   GO; GO:0072709; P:cellular response to sorbitol; IDA:UniProtKB.
DR   GO; GO:0034644; P:cellular response to UV; IDA:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IMP:BHF-UCL.
DR   GO; GO:0006970; P:response to osmotic stress; IDA:UniProtKB.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; IDA:UniProtKB.
DR   CDD; cd07879; STKc_p38delta; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR003527; MAP_kinase_CS.
DR   InterPro; IPR008352; MAPK_p38-like.
DR   InterPro; IPR038785; p38delta.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR01773; P38MAPKINASE.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01351; MAPK; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell cycle; Kinase;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Stress response; Transcription;
KW   Transcription regulation; Transferase.
FT   CHAIN           1..365
FT                   /note="Mitogen-activated protein kinase 13"
FT                   /id="PRO_0000186286"
FT   DOMAIN          25..308
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOTIF           180..182
FT                   /note="TXY"
FT   ACT_SITE        150
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         31..39
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         54
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         47
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18088087"
FT   MOD_RES         180
FT                   /note="Phosphothreonine; by MAP2K3, MAP2K4, MAP2K6 and
FT                   MAP2K7"
FT                   /evidence="ECO:0000269|PubMed:9374491"
FT   MOD_RES         182
FT                   /note="Phosphotyrosine; by MAP2K3, MAP2K4, MAP2K6 and
FT                   MAP2K7"
FT                   /evidence="ECO:0000269|PubMed:9374491"
FT   MOD_RES         350
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   VAR_SEQ         204..256
FT                   /note="VDIWSVGCIMAEMLTGKTLFKGKDYLDQLTQILKVTGVPGTEFVQKLNDKAA
FT                   K -> GQILHPVPATDPQEGFHSAVPTGQPPGCGPAGEDAGARRGQAPDGRAGPHPSL
FT                   (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_056558"
FT   VAR_SEQ         257..364
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_056559"
FT   VARIANT         41
FT                   /note="S -> L (in dbSNP:rs55776345)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042267"
FT   VARIANT         282
FT                   /note="A -> V (in dbSNP:rs55990045)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042268"
FT   VARIANT         300
FT                   /note="A -> T (in dbSNP:rs41270090)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042269"
FT   MUTAGEN         180
FT                   /note="T->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:9374491"
FT   MUTAGEN         182
FT                   /note="Y->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:9374491"
FT   CONFLICT        13..14
FT                   /note="DV -> EL (in Ref. 4; AAC51374)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        39
FT                   /note="V -> W (in Ref. 4; AAC51374)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        56
FT                   /note="L -> P (in Ref. 3; AAC51758)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        166
FT                   /note="I -> V (in Ref. 3; AAC51758)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        224
FT                   /note="K -> R (in Ref. 3; AAC51758 and 5; AAD23377)"
FT                   /evidence="ECO:0000305"
FT   HELIX           4..8
FT                   /evidence="ECO:0007829|PDB:3COI"
FT   STRAND          9..14
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   STRAND          17..22
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   STRAND          25..33
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   STRAND          35..44
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   TURN            45..47
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   STRAND          50..56
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   HELIX           63..78
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   STRAND          88..91
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   STRAND          95..97
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   STRAND          104..108
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   STRAND          111..113
FT                   /evidence="ECO:0007829|PDB:3COI"
FT   HELIX           114..117
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   HELIX           124..143
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   HELIX           153..155
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   STRAND          156..158
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   STRAND          164..166
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   HELIX           186..188
FT                   /evidence="ECO:0007829|PDB:4MYG"
FT   HELIX           191..195
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   TURN            196..198
FT                   /evidence="ECO:0007829|PDB:4MYG"
FT   HELIX           204..218
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   STRAND          222..226
FT                   /evidence="ECO:0007829|PDB:3COI"
FT   HELIX           228..239
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   HELIX           244..247
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   HELIX           253..261
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   HELIX           270..273
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   HELIX           279..288
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   TURN            293..295
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   HELIX           299..303
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   HELIX           306..308
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   TURN            309..311
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   HELIX           314..316
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   HELIX           327..329
FT                   /evidence="ECO:0007829|PDB:4YNO"
FT   HELIX           335..347
FT                   /evidence="ECO:0007829|PDB:4YNO"
SQ   SEQUENCE   365 AA;  42090 MW;  52E749EDB2973DDF CRC64;
     MSLIRKKGFY KQDVNKTAWE LPKTYVSPTH VGSGAYGSVC SAIDKRSGEK VAIKKLSRPF
     QSEIFAKRAY RELLLLKHMQ HENVIGLLDV FTPASSLRNF YDFYLVMPFM QTDLQKIMGM
     EFSEEKIQYL VYQMLKGLKY IHSAGVVHRD LKPGNLAVNE DCELKILDFG LARHADAEMT
     GYVVTRWYRA PEVILSWMHY NQTVDIWSVG CIMAEMLTGK TLFKGKDYLD QLTQILKVTG
     VPGTEFVQKL NDKAAKSYIQ SLPQTPRKDF TQLFPRASPQ AADLLEKMLE LDVDKRLTAA
     QALTHPFFEP FRDPEEETEA QQPFDDSLEH EKLTVDEWKQ HIYKEIVNFS PIARKDSRRR
     SGMKL
//
